Deutsche Bank Reiterates Buy On Intercept Pharmaceuticals, $500 PT


In a research report issued today, Deutsche Bank analyst Alethia Young reiterated a Buy rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with a price target of $500.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Alethia Young has a total average return of 0.1% and a 54.5% success rate. Young has a -18.3% average return when recommending ICPT, and is ranked #2253 out of 3337 analysts.